PharmaShots | Incisive News in 3 Shots

Subscribe Now

Clarity Pharmaceuticals

Clarity Pharmaceuticals Reports First Patient Dosing in P-I/IIa Study (CL04) of the 64Cu/67Cu Sartate to Treat Neuroblastoma

Clarity Pharmaceuticals Reports First Patient Dosing in P-I/IIa Study (CL04) of the 64Cu/67Cu Sartate to Treat Neuroblastoma

February 28, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us